Agnico Eagle Mines earnings beat by $0.19, revenue topped estimates
Investing.com -- Redcare Pharmacy shares climbed over 2% Friday following the release of their preliminary first quarter sales numbers for 2025, which met market expectations.
The company’s continued expansion of its customer base appears to be the primary driver behind the positive market sentiment.
The healthcare provider reported a 28% increase in sales to €717 million, slightly below the consensus estimate of €721 million.
Over-the-counter (OTC) sales saw a 20% rise, while prescription sales in Germany surged an impressive 191% year-on-year (YoY) to €108 million, representing an 11% sequential growth from the fourth quarter of 2024.
Analysts have highlighted Redcare’s customer growth as a significant positive, with Stifel commenting, "One of the key positives is the continued customer growth as the customer base increased from 12.5m at the end of FY24 to 13.1m."
This growth indicates a solid expansion strategy and suggests that the company is successfully capturing more market share.
Despite the slight miss in sales compared to consensus, the market’s reaction was favorable, focusing on the substantial growth in the German prescription market, which outpaced expectations of a 195% increase.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.